For decades, millions of women have been told they have polycystic ovary syndrome, or PCOS. But experts now say that name is misleading. In a major shift, the condition has been officially renamed polyendocrine metabolic ovarian syndrome, or PMOS. The change, backed by a global consensus of doctors and patients, aims to clear up confusion and improve care for the one in eight women affected worldwide.

This is not just a simple rebranding. The new name reflects a deeper understanding of what is actually happening inside the body. For many women, the term “polycystic ovaries” has caused unnecessary worry and misdiagnosis. The hope is that PMOS will help patients and doctors alike see the bigger picture of this complex health issue.

Why the Old Name Was a Problem

The original name, PCOS, has been used for years. But it has long been criticized as inaccurate. The word “polycystic” suggests that the ovaries are filled with cysts. In reality, women with the condition often have many small, immature follicles — not harmful cysts. This distinction matters because many women develop ovarian cysts at some point in their lives, and they may wrongly believe they have PCOS.

Experts involved in the name change say this confusion has real consequences. Up to 70 percent of women with the condition may go undiagnosed. That means millions of women are missing out on treatment and support. The old name also focused too heavily on the ovaries, ignoring the fact that PMOS affects many other systems in the body.

Dr. Helena Teede, a researcher at Monash University in Australia, led the effort to change the name. She and her team published their findings in The Lancet. They argue that the old name does not capture the full scope of the condition. “This change was driven with and for those affected by the condition,” Teede said in a press release. “We are proud to have arrived at a new name that finally accurately reflects the complexity of the condition.”

What the New Name Means

The new name, polyendocrine metabolic ovarian syndrome, or PMOS, is more detailed. Let’s break it down:

• Polyendocrine — This refers to the fact that the condition affects multiple hormone-producing glands in the body, not just the ovaries.
• Metabolic — This highlights the metabolic issues that often come with the condition, such as insulin resistance, weight gain, and a higher risk of type 2 diabetes.
• Ovarian — The ovaries are still involved, but they are just one part of a larger picture.
• Syndrome — This word is kept because PMOS is a collection of symptoms, not a single disease.

By dropping the misleading “polycystic” label, experts hope patients will have a clearer understanding of their health. The new name also avoids the stigma and confusion that came with the old one.

How PMOS Affects the Body

PMOS is far more than a reproductive issue. It is a multisystem condition that can impact many areas of health. While it is often thought of as a gynecological problem, it also involves endocrine, metabolic, psychological, and dermatological factors.

Common symptoms include irregular periods, excess hair growth, acne, and difficulty getting pregnant. But many women also experience metabolic problems like insulin resistance, which can lead to weight gain and an increased risk of type 2 diabetes. Mental health challenges, including anxiety and depression, are also common.

Dr. Rachel Weinerman, a reproductive endocrinologist at Case Western Reserve University, told MedPage Today that the name change is long overdue. She explained that the old term “polycystic” led to unnecessary confusion. Many patients thought that having a simple ovarian cyst meant they had PCOS. “PMOS is a metabolic condition that affects multiple parts of a woman’s health, including her reproductive function,” she said.

Dr. Anuja Dokras, a women’s health researcher in Philadelphia, added that she hopes the new name will help doctors in different specialties recognize the condition earlier. “This will allow for early diagnosis and more comprehensive counseling regarding risks associated with this syndrome,” she said.

How the Name Change Was Decided

This was not a quick or simple decision. The global consensus process involved 56 major academic, clinical, and patient organizations. It was led by Monash University’s Centre for Research Excellence in Women’s Health in Reproductive Life, the Androgen Excess and PCOS Society, and the U.K.-based charity Verity.

The team conducted surveys that reached more than 10,000 patients and nearly 4,000 health professionals around the world. They also held workshops and ran marketing and communication analyses to test potential new names.

Key priorities for the new name included scientific accuracy, clarity, avoiding stigma, cultural appropriateness, and ease of use in different languages. The team also wanted a name that would not be confused with other medical conditions.

The top choice at first was “polyendocrine metabolic ovulatory syndrome.” But after more discussion, it was revised to the final name: polyendocrine metabolic ovarian syndrome.

What This Means for You

If you or someone you know has been diagnosed with PCOS, this name change may feel like a big shift. But experts say it is a positive step. The new name should help reduce confusion and lead to better care.

For women who have not yet been diagnosed, the hope is that doctors will now be more likely to consider PMOS when they see a range of symptoms — not just irregular periods or ovarian issues. This could lead to earlier diagnosis and treatment.

It is important to remember that the diagnostic criteria for the condition have not changed. Under international guidelines, adults aged 20 and older are diagnosed if they meet two of the following criteria, after ruling out other conditions:

• Irregular or absent ovulation (oligoanovulation)
• Signs of high androgen levels (clinical or biochemical hyperandrogenism)
• Polycystic ovaries on ultrasound or elevated anti-Müllerian hormone levels

For adolescents, the first two criteria are required. The name change does not alter how the condition is diagnosed or treated — it simply aims to improve understanding.

What Experts Say About the Change

Many doctors and researchers support the new name. Dr. Weinerman said it will take time for patients and physicians to adjust, but she believes PMOS will ultimately benefit patients. “It will lead to less confusion over irrelevant cysts,” she said.

Dr. Dokras echoed that sentiment. She said the new name brings greater awareness to the condition, which could help doctors in different specialties — not just gynecologists — recognize and treat PMOS. This is important because PMOS affects so many aspects of health, from metabolism to mental well-being.

Experts also emphasize that the name change was driven by patients themselves. The surveys and workshops included thousands of women living with the condition. Their voices helped shape the final decision.

Practical Takeaways for Readers

If you have been diagnosed with PCOS, or if you suspect you may have PMOS, here are some key points to keep in mind:

• Don’t panic about the name change. Your diagnosis and treatment plan remain the same. The new name simply gives a more accurate picture of your health.
• Talk to your doctor. If you have questions about PMOS, bring them up at your next appointment. Ask about metabolic health, including blood sugar and insulin levels.
• Focus on whole-body health. PMOS is not just about the ovaries. Lifestyle changes, such as a balanced diet and regular exercise, can help manage metabolic symptoms.
• Seek support. Organizations like Verity offer resources and community for women with PMOS. You are not alone.
• Stay informed. The new name will be gradually integrated into health systems over the next three years. International guidelines will be updated in 2028.

What Happens Next

The team behind the name change has already started an eight-stage plan to roll out the new term. This includes publishing the findings in medical journals, working with health systems to update records and materials, and eventually updating international guidelines that are used by 195 countries.

There are some limitations to the process. The surveys had a disproportionate number of responses from higher-income countries, which may not fully represent all regions. There is also a possibility of selection bias, meaning the people who responded may have different views than the general population.

Still, experts are optimistic. They believe the new name will help millions of women around the world get the care and understanding they deserve.

The Bottom Line

PMOS is a common but complex condition that affects one in eight women — about 170 million people globally. For too long, the old name led to confusion and delayed diagnosis. The new name, polyendocrine metabolic ovarian syndrome, reflects the reality of the condition: it is a multisystem disorder that involves hormones, metabolism, and more.

While it may take time for the new name to catch on, experts agree that this change is a step in the right direction. It puts patients first, improves clarity, and opens the door to better care. If you or someone you know is affected by PMOS, now is a good time to learn more and take charge of your health.

Source: MedPage Today